AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 103 min read$QGEN

Understanding Qiagen (QGEN) Reliance on International Revenue

Qiagen (QGEN) reported total revenue of $535.04 million for the quarter ended June 2026, up 0.3%. International segment revenue included $72 million from Asia Pacific, Japan and Rest of World (13.5%), and $178 million from Europe, Middle East and Africa (33.3%). Analysts projected $541.05 million total revenue for the current fiscal quarter.

Original reporting
finance.yahoo.com
Published Aug 10, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 3:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Understanding Qiagen (QGEN) Reliance on International Revenue — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$QGENNeutralLow
01

Why it matters

Traders may use the regional revenue mix and the reported vs consensus “surprise” figures to refine short-term expectations, but there is no new guidance or event catalyst.

02

Market read

Regional revenue mix (Asia Pacific, Japan and RoW; EMEA) is quantified and compared to consensus, offering incremental context for earnings modeling.

03

What to watch

The article does not provide segment margins, FX rates, or management commentary, which are typically more important for translating revenue mix into earnings power.

Relevance 4/10Novelty 4/10Timing: quarter ended June 2026, published pre-market/early session

Background

The piece frames international revenue reliance as a key lens for financial resilience, then breaks out Qiagen’s regional revenue contributions for the quarter ended June 2026.

Company-level read

Ticker impact

$QGENNeutralLow confidence
Context

Qiagen reports overseas revenue mix for the quarter ended June 2026, including Asia Pacific, Japan and RoW at $72M and EMEA at $178M.

Expected impact

Limited, unless traders treat the regional “surprises” as a signal of accelerating or weakening demand in specific geographies.

Evidence & confidence

It is an analysis-style breakdown of reported quarterly regional revenue versus consensus, without new guidance, filings, or management commentary.

Market effects

Sector

Regional diagnostics demand and currency effects may influence sentiment toward diagnostic products peers, but the article is not a sector-wide catalyst.

Regional

Highlights relative contribution from Asia Pacific, Japan and RoW versus EMEA, which can affect how traders think about geographic growth and FX sensitivity.

Global

No direct global macro policy or cross-asset linkage is introduced beyond general international revenue framing.

Counterpoint

What could challenge this read

Regional “surprises” are small in magnitude versus consensus, so they may not warrant repricing beyond normal quarterly noise.

Key entities

  • company
    Qiagen

    Diagnostics products maker; article details its regional revenue contributions and compares them to Wall Street consensus estimates.

Read at source← All news

Related articles

AUG 15
$QGENHighAI 9/10

QGEN Stock Slumps After-Hours On Guidance Cut Tied To Weak TB Test Demand

QIAGEN N.V. (QGEN) shares fell about 6% after hours after it cut fiscal 2026 guidance. The company now expects adjusted diluted EPS of at least $2.43 at constant exchange rates, down from $2.50, and net sales growth of 1-2% versus at least 5%. It cited weaker QuantiFERON TB test demand, including lower U.S. immigration testing. Q1 net sales were $492M and adjusted EPS $0.54 CER.

stocktwits.com4 min
AUG 13
$QGENMed

Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?

Qiagen (QGEN) reported Q2 2026 net sales of $535 million, flat vs a guidance call for about a 2% decline, and adjusted diluted EPS of $0.62, ahead of outlook, according to the company. Growth pillars rose 5% CER, but diagnostics and PCR sales fell and margins slipped to 29.4% from 29.9%. Full-year relies on new launches and easier comparisons.

insidermonkey.com7 min
AUG 13
$QGENMedAI 8/10

Qiagen (QGEN) Q2 2026 Earnings Call Transcript

Qiagen (QGEN) reported Q2 2026 adjusted diluted EPS of $0.62 at constant exchange rates, above its outlook of at least $0.60. Growth pillars rose 5% at CER, with Sample Technologies up 9% CER and QIAcuity delivering double-digit growth. Adjusted operating income was $157 million (29.4% margin). Operating cash flow was $301 million for 6 months, and the company increased its 2026 dividend 40% to $0.35.

yahoo.com7 min
AUG 9
$QGENMedAI 8/10

Qiagen Q2 Earnings Call Highlights

QIAGEN reported Q2 genomics and NGS sales up 2% at constant exchange rates, with QIAGEN Digital Insights growing single digits and universal NGS panel consumables for third-party sequencers rising over 20%. Adjusted operating income fell 2% to $157M, margin 29.4%. Operating cash flow was $301M for 1H. QGEN reaffirmed FY sales growth of ~1% to 2% and adjusted diluted EPS at least $2.43.

yahoo.com6 min
AUG 8
$QGENMedAI 8/10

QIAGEN Beats Q2 2026 Guidance, Reaffirms Full-Year Outlook Amid Mixed Demand

QIAGEN reported Q2 2026 net sales of $535 million, flat year over year and ahead of guidance for a decline, with growth from Sample technologies, QIAcuity and QIAGEN Digital Insights offsetting weaker instrument demand. Adjusted diluted EPS was $0.62 versus outlook of at least $0.60, with 29.4% adjusted operating margin and $301 million operating cash flow in H1. The company reaffirmed full-year 2026 guidance of 1–2% net sales growth and adjusted diluted EPS of at least $2.43.

theglobeandmail.com3 min
AUG 5
$QGENMed

QIAGEN Q2 Profit Rises

QIAGEN N.V. (QGEN) reported higher second-quarter profit. The company reaffirmed its full-year 2026 outlook. Non-GAAP EPS was $0.62, beating by $0.02, and revenue was $535 million, above estimates by $7.54 million, according to the report.

finanznachrichten.de2 min